Tag:
ataluren
Latest Headlines
Latest Headlines
Genzyme gives back drug rights to PTC Therapeutics
Genzyme is walking away from a troubled program at PTC Therapeutics after spending $100 million back in 2008 to gain rights in certain markets for ataluren, which is being evaluated to treat rare
PTC's lead drug ataluren flunks PhIIb
PTC Therapeutics' lead drug ataluren failed a Phase IIb trial, flunking a test of its ability to improve the physical performance of patients with a rare genetic disorder. Genzyme is partnered on the
PTC picks up $50M in financing
PTC Therapeutics got an early Christmas gift this morning in the form of $50 million in financing. The round--PTC's first syndicated equity financing round in over four years--was led by new investor
